Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
News|Articles|January 22, 2024
Apply for a 2024 AUGS Foundation Grant
Author(s)American Urogynecologic Society
Advertisement
Foundation research funds are made available to qualified American Urogynecologic Society (AUGS) members to pursue their research question. The goals of the mentored
Application Deadline: March 19, 2024
Applicants can
- AUGS Foundation Fellow Research Award: A grant awarded to a fellow for clinical/patient-oriented, educational, or lab-based/basic science research.
- AUGS Foundation Faculty Research Award: A grant awarded to an early career researcher or affiliate member for clinical/patient-oriented, educational, or lab-based/basic science research.
- June Allyson Memorial Fund Research Award: A grant awarded to a fellow for lab-based/basic science research.
Advertisement
Related to this article
These FAQs outline key recommendations and practical takeaways from the AUA/SUFU/AUGS Genitourinary Syndrome of Menopause guideline.
Brian I. Rini, MD, FASCO, explains why LITESPARK-012’s negative triplet results still offer lessons on drug delivery and building on first-line RCC doublets.
Topline results from the study are anticipated in the first half of 2027.
The 2026 LUGPA Annual Meeting will tackle policy, artificial intelligence, and practice growth, according to Benjamin H. Lowentritt, MD, FACS.
JNJ-6143 demonstrated promising PSA and tumor response rates with an encouraging safety profile in heavily pretreated mCRPC, including across genomic subgroups.
Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.
In a POTOMAC subgroup analysis, durvalumab plus BCG reduced the risk of high-risk recurrence or death by 44% vs BCG alone in patients with papillary-only, BCG-naive NMIBC.
Advertisement
Advertisement
Trending on Urology Times
1
Novel RIPTAC molecule shows promising activity in heavily pretreated mCRPC
2
Updated CAPItello-281 data show numerical OS benefit with capivasertib in PTEN-deficient mHSPC
3
LUGPA 2026: Midterms, AI, and ancillary services take center stage
4
CLARIFY trial reaches enrollment target for 64Cu-SAR-bisPSMA in prostate cancer
5